Humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof

An antibody and neutralization technology, applied in the direction of antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of not improving the treatment process of patients and not significantly reducing the mortality rate of the new coronavirus, and achieving the effect of high antigen affinity

What is AI technical title?
AI technical title is built by PatSnap AI team. It summarizes the technical point description of the patent document.
An antibody and neutralization technology, applied in the direction of antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of not improving the treatment process of patients and not significantly reducing the mortality rate of the new coronavirus, and achieving the effect of high antigen affinity

CN112341541AActive Publication Date: 2021-02-09中国疾病预防控制中心病毒病预防控制所

3 Cites 9 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.

Viewing Examples

Smart Image

Examples

Experimental program

Comparison scheme

Effect test

Embodiment 1

[0029] Example 1 Preparation and function of human-derived anti-new coronavirus neutralizing antibody nCoV-163

[0030] 1. Materials

[0031] 1. Samples and carriers: New coronavirus antibody-positive serum and lymphocytes: provided by Wuhan CDC and Shandong CDC. The strain XLI-Blue was purchased from Stratagene Corporation of the United States, and the antibody library construction vector pComb3H (40kb) was donated by the Scripps Research Institute of the United States.

[0032] 2. Antigen: 2019-nCoV RBD protein and S1 protein were provided by Hualan Bioengineering Co., Ltd., 2019-nCoV S protein trimer was provided by Jiangsu Dongkang Biomedical Technology Co., Ltd. RBD protein expression plasmid and S protein full-length Expression plasmids (see Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, DongY, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y ,Xia L,Fu L,Hou L,Xu J,Yu C,Li J,Zhou Q,Chen W.Aneutralizing human antibody binds to the N-terminal domain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

PUM

Login to View More

Abstract

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof. According to the humanized anti-novel coronavirus neutralizing antibody nCoV-163 andthe application thereof, the humanized neutralizing antibody nCoV-163 specifically aiming at a novel coronavirus surface antigen is successfully obtained by utilizing a phage antibody library technology, the antibody nCoV-163 is provided with a neutralizing function of preventing novel coronavirus from infecting sensitive cells in vitro and is high in antigen affinity, and the antibody is expectedto be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to human-derived anti-new coronavirus neutralizing antibody nCoV-163 and its application. Background technique [0002] The novel coronavirus SARS-CoV-2 is a new virus discovered in 2019 that can cause viral pneumonia, or lung infection, in humans. The coronavirus genome sequentially encodes the spike protein, envelope protein, membrane protein and nucleocapsid protein. Among them, the spike protein (Spike) is the most important surface membrane protein of coronavirus, which contains two subunits S1 and S2, of which S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the receptors of cells. The SARS-CoV-2 spike protein interacts with human angiotensin-converting enzyme 2 (ACE2) to infect human respiratory epithelial cells. [0003] Although multiple drugs such as remdesivir, hydroxychloroquine, lopinavir, and interferon β1a have been prov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

Application Information

Patent Timeline

09 Feb 2021

Publication

CN112341541A

IPC: C07K16/10; C12N15/13; A61K39/42; A61P31/14

CPC: C07K16/10; A61P31/14; A61K2039/505; C07K2317/565

Inventors: 梁米芳; 孙丽娜